Longeveron touts PhIIa Alzheimer’s data, but drug’s future remains murky

Longeveron re­leased an up­date from a small Phase IIa Alzheimer’s study Thurs­day morn­ing, claim­ing to show a win at the drug’s low dose. But ques­tions re­main over its ef­fi­ca­cy at high­er dos­es and the com­pa­ny’s next steps.

In a 49-pa­tient tri­al test­ing the drug at three dif­fer­ent dose lev­els, on­ly the low­est dose achieved a pre-spec­i­fied sta­tis­ti­cal sig­nif­i­cance com­pared to place­bo af­ter 39 weeks. For their p-val­ue, Longeveron re­searchers used a two-sided al­pha of p<0.1, and the low dose came in at p=0.091, just un­der the study’s thresh­old. Re­searchers mea­sured the drug’s ef­fect us­ing the Com­pos­ite Alzheimer’s Dis­ease Score, or CADS.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.